Key Takeaways
- Strong quarter, volume and price both up: Revenue grew ~45% YoY, with volume up 10% QoQ and realizations up 19% QoQ, driven by a richer mix of special and premium MCC grades.
- Margins hit a sustainable 21–22% EBITDA: Material costs fell to 47% of revenue from 51% last year, and management confirmed this level is sustainable for the full year and beyond.
- Diversification push is real but early: The company launched nutraceutical premixes, entered OTC healthcare via a capital-light contract manufacturing model, and incorporated a Dubai subsidiary for MENA sales, all while the ethanol project looks increasingly unlikely.
- Capacity expansion is the core growth engine: 7,000 MT of new MCC capacity arrives in Q4 FY23, with 60% utilization targeted in FY24, and the greenfield CCS facility is progressing through environmental clearances.
- What to watch next quarter: Whether wood pulp prices stabilize as hoped by H1 end, the pace of new capacity commissioning, and any concrete revenue or margin data from the nutrition and OTC segments.
Top-Line Performance & Realization
- Volume and value both grew: Q1 volume grew 10% QoQ while value grew ~19–20% QoQ, with value outpacing volume because of a healthier sales mix weighted toward special and premium grades.
- Realization jumped sharply: Average selling price rose to ~₹217 (or $216.79) from ₹182 last year, and management stated it "will only get better" as the special-grade portion of sales keeps increasing.
- Export share climbed: Exports rose to 75.43% of sales from 73.6% a year ago, helped by marketing efforts and product customizations that expanded the global client base.
- Rupee depreciation is a tailwind: With ~75% of products exported, a weaker rupee is favorable, and the company has been able to pass raw material cost increases through to customers.
- Inflation has not dented demand: Management sees no demand impact from rising global inflation because the business primarily serves the pharmaceutical industry, with US sales actually pulling up more.
Amit Raj Sinha: "We of course are seeing rising inflation. But however, we have not really seen it impacting our demand. The prime reason is that we primarily catering to the Pharmaceutical industry, which is not new so we don't see decrease in demand in any way."
Margin Structure & Sustainability
- Material cost ratio improved: Consumption of material fell to 47% of revenue from 51% in Q1 FY22, driven by cost-effective processes and a favorable product mix.
- EBITDA margin reached 21–22%: The improvement came from focus on high-margin products, cost-effective manufacturing, and effective inventory management.
- Sustainability confirmed: Management stated these margins are sustainable in future, with the trend of reduced material consumption expected to continue.
- Mix shift is the structural driver: The sales mix is changing toward special and premium grades that carry higher margins, and this shift is expected to continue.
- Wood pulp cost pass-through is working: The company is currently able to pass increased pulp prices on to customers, providing comfort, though pulp prices continued rising into Q2 rather than stabilizing as initially hoped.
Amit Raj Sinha: "We have seen is that, at this moment we are able to pass on the increased pulp prices onto the customers. So that's a very big comfort."
Capacity Expansion & Capex Cycle
- MCC brownfield expansion on track: Two facilities at Dahej and Jhagadia are under expansion, with the unspent ₹16 Crores to be completed before the last quarter of FY23.
- 7,000 MT arriving in Q4 FY23: The new capacity will contribute a very small portion in Q4 itself, with management targeting 60% utilization of the increased capacity in FY24.
- Existing plants are nearly full: Current facilities are operating at ~95% utilization, making the expansion critical for near-term volume growth.
- CCS greenfield project is in the approval pipeline: Land at Dahej has been procured and environmental clearance applications are in process, a step that takes 6–12 months; management will not commit a commissioning date until EC is in hand.
- No capex for new ventures: The OTC and human nutrition segments are being built without manufacturing capex, keeping the investment cycle focused on MCC and CCS.
Amit Raj Sinha: "We really are not able to commit you update, but once the EC clearances in place we will definitely have a date to it because everything else is already structured in the project management team members."
New Ventures: Nutrition, OTC & Dubai
- Human nutrition launched: The company entered nutraceutical premixes for fortified foods and beverages, targeting private, institutional B2G tender-based, and pharmaceutical premix segments.
- Leased facility, no capex: Manufacturing is in-house at a leased premix facility costing ₹1.85 lakhs/month on a 10-year lease, with no capex incurred.
- Revenue potential is modest for now: Current-year turnover may reach ₹18–20 Crores, with potential of not less than ₹50 Crores, and the segment is expected to be EBITDA-positive this year.
- OTC entry is capital-light: Products will be contract-manufactured by trusted players in North India and sold through the company's own sales and marketing network, generating incremental revenue with minimum capital.
- Margins will start lower: Initial OTC and nutrition margins will be below excipient lines, but management expects them to return to the base 20% EBITDA level as the product portfolio expands.
- Dubai subsidiary incorporated: A sales presence for the Middle East and North Africa, with a CEO appointed and local sales team hiring underway; no manufacturing capex, only operational expenditure.
Amit Raj Sinha: "We would have little lower EBIDTA compared to our excipient lines on account of Nutritional and OTC segment in the initial phase. However, as we continue to service and continue to expand our product portfolio, we believe that we should be able to come back to our base margin of 20% EBITDA."
Competitive Positioning & Customer Profile
- MCC margins compare favorably: Management stated that on an MCC-to-MCC portfolio comparison, Sigachi's margins are better than Gujarat Micro Wax, even though the competitor's overall margins appear higher due to a different product mix.
- Innovator customer acquisition is still work in progress: Historically, innovator pharmaceutical companies work with the world's number-one supplier; Sigachi has been trying to break in but has not yet succeeded at scale.
- Signet's pricing premium explained: Signet's higher realizations (~₹6 Lac/MT) reflect its role as a trading house selling imported products from global leaders like DuPont, a depreciated rupee conversion effect, a better product mix, and a customer base of primarily innovator companies who pay a premium.
Amit Raj Sinha: "Their customer profiles are primarily the innovators. And historically, innovative companies have been working with the world number one. We have been trying to get into the innovative companies, but it is still work in progress..."
Ethanol Project Status
- Project is in abeyance and leaning toward cancellation: Management is "mentally going on the other side of the border," feeling it might not be the best thing to do, and is looking at alternatives.
- Reasons for hesitation: Certain aspects of the ethanol business are very different from Sigachi's core operations, and some factors are not entirely in the government's control, making the outlook uncertain.
- Decision expected in a couple of months: A consultant has been appointed to explore feasibility, and the board will take an official decision soon, with management indicating they "possibly might actually not be going ahead."
Amit Raj Sinha: "We realize that there are certain aspects of this which are of course very, very different from what we do and certain aspects which are not entirely in control of the government. So it is not that government is going to be positive about it, so at this moment we are exploring and seeing which way it aligns with our overall purpose and possibly we might actually not be going ahead..."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue CAGR | Maintain the CAGR achieved over the last three years | Ongoing |
| MCC capacity addition | 7,000 MT to become operational | Q4 FY23 |
| New capacity utilization | Achieve 60% utilization of increased capacity | FY24 |
| Jhagadia & Dahej capex completion | Unspent ₹16 Crores to be fully spent | Before last quarter of FY23 |
| EBITDA margin sustainability | 21–22% EBITDA margin sustained | Full year FY23 and next year |
| Nutrition & OTC margin recovery | Return to base margin of 20% EBITDA | As product portfolio expands (undated) |
| Ethanol decision | Board to take official go/no-go decision | In a couple of months |
| CCS commissioning date | Will provide a date once EC clearance is in hand | After EC clearance (6–12 months process) |
| Royalty structure alignment | Do homework on aligning royalty to bottom line vs top line | Undated commitment |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Operational revenue | ₹78 cr, +43% YoY |
| EBITDA | ₹16 cr, +34% YoY |
| EBITDA margin | 20.82% |
| Net profit | Not stated |
| Volume growth | ~10% QoQ |
| Realization growth | 19% QoQ |
| Average selling price | ₹217, vs ₹182 in Q1 FY22 |
| Export sales share | 75.43%, vs 73.6% in Q1 FY22 |
| Material consumption | 47% of revenue, vs 51% in Q1 FY22 |
| Total capacity | >13,000 MTPA, expanding to 20,000 MTPA via ongoing capex |
| Capacity addition expected | 7,000 MTPA, in later part of FY23 |
| Existing capacity utilization | ~95% |
| Premix facility expected FY23 revenue | ₹18–20 cr |
| Raw material price | $828–$830 per metric ton average, up from $650 |
| Employee strength | 900 |